OpenNashEarnings

Life Sciences · NYSE: DHR

Danaher earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 27 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Danaher's new CEO is shifting from reshaping the portfolio to connected selling and AI-driven science, launching an autonomous lab and partnering with NVIDIA to turn breadth into a growth edge.

Demand improved across Danaher's end markets. Bioprocessing orders grew mid-teens, led by upstream consumables and resins. Non-respiratory diagnostics grew 7%, helped by Beckman Coulter's strongest quarter in more than two years and Cepheid's non-respiratory tests. The company announced its first AI-powered autonomous lab, a partnership with NVIDIA, and work with Anthropic on instrument connectivity. Leica Biosystems closed its StatLab acquisition, and Masimo kept growing at a high single-digit pace.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗

Quarters

KPI history

Revenue$6.6B+8.3% y/yQ3 2026
Q4 2024: $6.5B (worked out from the annual figure)Q4 ’24$6.5BQ1 2025: $5.7BQ1 ’25$5.7BQ2 2025: $5.9BQ2 ’25$5.9BQ3 2025: $6.1BQ3 ’25$6.1BQ4 2025: $6.8B (worked out from the annual figure)Q4 ’25$6.8BQ1 2026: $6.0BQ1 ’26$6.0BQ2 2026: $6.3BQ2 ’26$6.3BQ3 2026: $6.6BQ3 ’26$6.6B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$6.5B *
Q1 2025$5.7B
Q2 2025$5.9B
Q3 2025$6.1B
Q4 2025$6.8B *
Q1 2026$6.0B
Q2 2026$6.3B
Q3 2026$6.6B
Diluted EPS (GAAP)$1.75+37.8% y/yQ3 2026
Q1 2025: $1.32Q1 ’25$1.32Q2 2025: $0.77Q2 ’25$0.77Q3 2025: $1.27Q3 ’25$1.27Q1 2026: $1.45Q1 ’26$1.45Q2 2026: $1.23Q2 ’26$1.23Q3 2026: $1.75Q3 ’26$1.75
Data
Q1 2025$1.32
Q2 2025$0.77
Q3 2025$1.27
Q1 2026$1.45
Q2 2026$1.23
Q3 2026$1.75

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin19.0%−0.1 pts y/yQ3 2026
Q4 2024: 21.8%Q4 ’2421.8%Q1 2025: 22.2%Q1 ’2522.2%Q2 2025: 12.8%Q2 ’2512.8%Q3 2025: 19.1%Q3 ’2519.1%Q4 2025: 22.0%Q4 ’2522.0%Q1 2026: 22.6%Q1 ’2622.6%Q2 2026: 18.0%Q2 ’2618.0%Q3 2026: 19.0%Q3 ’2619.0%
Data
Q4 202421.8%
Q1 202522.2%
Q2 202512.8%
Q3 202519.1%
Q4 202522.0%
Q1 202622.6%
Q2 202618.0%
Q3 202619.0%
Free cash flow$1.6B+19.1% y/yQ3 2026
Q4 2024: $1.5BQ4 ’24$1.5BQ1 2025: $1.1BQ1 ’25$1.1BQ2 2025: $1.1BQ2 ’25$1.1BQ3 2025: $1.4BQ3 ’25$1.4BQ4 2025: $1.7BQ4 ’25$1.7BQ1 2026: $1.1BQ1 ’26$1.1BQ2 2026: $1.3BQ2 ’26$1.3BQ3 2026: $1.6BQ3 ’26$1.6B
Data
Q4 2024$1.5B
Q1 2025$1.1B
Q2 2025$1.1B
Q3 2025$1.4B
Q4 2025$1.7B
Q1 2026$1.1B
Q2 2026$1.3B
Q3 2026$1.6B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$6.5Bd$5.7B$5.9B$6.1B$6.8Bd$6.0B$6.3B$6.6B
Gross margin59.5%61.2%59.3%58.2%58.0%60.3%57.6%58.5%
Operating income$1.4Bd$1.3B$760.0M$1.2B$1.5Bd$1.3B$1.1B$1.2B
Operating margin21.8%22.2%12.8%19.1%22.0%22.6%18.0%19.0%
Net income$1.1Bd$954.0M$555.0M$908.0M$1.2Bd$1.0B$870.0M$1.2B
Diluted EPS—$1.32$0.77$1.27—$1.45$1.23$1.75
Operating cash flow$2.0Bd$1.3B$1.3Bd$1.7Bd$2.1Bd$1.3B$1.5Bd$1.9Bd
Capital expenditure$516.0Md$245.0M$248.0Md$292.0Md$371.0Md$237.0M$269.0Md$255.0Md
Free cash flow$1.5B$1.1B$1.1B$1.4B$1.7B$1.1B$1.3B$1.6B
R&D expense$442.0Md$379.0M$403.0M$378.0M$438.0Md$387.0M$412.0M$433.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings